Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

ANNAPOLIS,Md.,Nov. 15,2022 -- Alphyn Biologics,a clinical-stage dermatology company developing first-in-class multi-target therapeutics,announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a,a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection,which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks.

The randomized,vehicle-controlled,double-blind trial is evaluating the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD. Enrollment is ongoing in a second cohort of the trial,which uniquely is investigating the treatment in AD patients who are also suffering from bacterial infections,including staphylococcus aureus,or Staph,and MRSA,the antibiotic-resistant Staph. Alphyn anticipates AB-101a will be effective against non-infected AD and infected AD and expects it will offer patients and physicians a comprehensive,safe,and convenient treatment option.

AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform has multiple bioactive compounds and,therefore,multiple mechanisms of action to potentially address multiple problems of any target disease. Alphyn began its clinical trial program in Phase 2 due to the strong safety profile of its AB-101 platform.

ABOUT ALPHYN BIOLOGICS

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate,AB-101a,is being developed as a topical treatment for atopic dermatitis (AD),the most common form of eczema. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's immune system and bacterial components,making it ideal for treating non-infected and infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and therefore multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety,efficacy and regulatory marketing authorization advantages. Alphyn is based in Annapolis,Maryland and Cincinnati,Ohio,and has a wholly owned Australia subsidiary. The company became operational in 2020 and has raised approximately $6.9 million.